Volume 350:1646-1654 April 15, 2004 Number 16 Management of Cirrhosis and Ascites Pere Ginès, M.D., Andrés Cárdenas, M.D., Vicente Arroyo, M.D., and Juan.

Slides:



Advertisements
Similar presentations
Learning objectives To understand the pathophysiologic basis for vasoactive therapies for HRS To become familiar with the diagnostic criteria for HRS To.
Advertisements

Acute Liver Failure.
Management of ascites in cirrhosis
CIRRHOSIS. Use of nonspecific has been studied extensively in randomized, controlled trials of the primary prophylaxis of variceal bleeding. β-adrenergic.
DIURETICS How do they work? What do they do? WHEN DO I USE THEM?
Cardinal Manifestation of Disease: EDEMA Dr. Meg-angela Christi Amores.
 60% of lean body weight = water  (2/3) intracellular.  (1/3)extracellular (interstitial fluid)  5% blood plasma.  edema = an accumulation of interstitial.
Edema Excess fluid in the tissues  Intracellular Edema  Extracellular Edema.
 Brian Torski, DO, Internal Medicine PGY-1.  Overview of Hepatorenal Syndrome o Pathophysiology o Diagnosis o Classification o Prevention and Treatment.
Management of ascites in patients with cirrhosis Treviso 4 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.
Lucy Adkinson.  Case history  Reminder of different causes  Update on recent NICE guidance.
Finishing Renal Disease Aging and death. Chronic Renal Failure Results from irreversible, progressive injury to the kidney. Characterized by increased.
CDI Education Cirrhosis 4/17/2017.
Complications of Liver Cirrhosis Ayman Abdo MD, AmBIM, FRCPC.
Blood Flow. Due to the pressure difference of two vessel ends.
The hepatorenal syndrome. Assessing kidney function in pts with cirrhosis  Cr assays are subject to interference by chromogens, bilirubin being the major.
Liver pathology: CIRRHOSIS
IV CURSO PARA RESIDENTES DE LA AEEH DIAGNÓSTICO Y TRATAMIENTO DE LAS ENFERMEDADES HEPÁTICAS Barcelona, de Octubre de 2013 ASCITIS Y SINDROME HEPATORRENAL.
HEPATORENAL SYNDROME – LIVER PERSPECTIVE Dr. S. Shivakumar M.D., Addl. Professor of Medicine, Govt.Stanley Medical College, Chennai – By.
HEPATO renal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine.
CONCEPTS OF NORMAL HEMODYNAMICS AND SHOCK
Acute Renal Failure and Cirhosis By Syed Rizwan, MD.
The Vicious Cycle of Chronic Congestive Heart Failure.
Hepatorenal Syndrome Dr Allister J Grant Leicester Liver Unit
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Creatinine (mg/dL) MonthsWeeks Therapeutic paracentesis Cefotaxime Type-2 HRSType-1 HRS Encephalopathy Jaundice CLINICAL TYPES.
C IRRHOSIS. A LCOHOLIC L IVER I NJURY : Alcoholic Liver disease - Patterns Fatty change, Acute hepatitis Chronic hepatitis Cirrhosis, Chronic Liver failure.
Complications of liver cirrhosis
Chapter 16 Serous Fluid Professor A. S. Alhomida
Complications of liver cirrhosis
Hipertensión Portal Dr. Michel Baró A.
Hypertension Robbins: 525 to 530, Cecil:
CLINICAL USE OF DIURETICS. PATHOGENESIS AND TREATMENT OF REFRACTORY EDEMA Determinants of diuretic response - site of action, antinatriuretic forces,
Management of patients with cirrhosis and refractory ascites Treviso 4 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of.
Ascites and Spontaneous Bacterial Peritonitis Arthur Harris, MD Attending, Division of Gastroenterology Jacobi Medical Center/North Central Bronx Hospital.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Abdominal Contributions to Cardiorenal Dysfunction.
Ascites 소화기내과 F1 김경엽.  Ascites: pathologic accumulation of fluid in the peritoneal cavity Causes of ascitesPercentage Cirrhosis81 % Cancer10 % Heart.
Definition  Is a chronic disease characterized by scaring and necrotic tissue replaced by fibrotic tissue. Resulting in hepatic insufficiency and portal.
Date of download: 6/21/2016 From: Pathogenesis of Hypertension Ann Intern Med. 2003;139(9): doi: / A pathway.
Bacterial translocation and Hemodynamic change in cirrhotic patients R3 김현수.
Short-term effects of combination of satavaptan, a selective vasopressin V 2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without.
Complications of liver cirrhosis. Recognize the major complications of cirrhosis. Understand the pathological mechanisms underlying the occurrence of.
The Kidney in Liver Disease
Kidney Injury and Liver Disease in the ICU
Interrelationships among renal function, Na+ intake, water homeostasis, distribution of extracellular fluid volume, and mean arterial blood pressure. Pathophysiological.
Cirrhosis Key features:
Multiple factors can predispose to decompensation in a patient with cirrhosis. Risk factors for decompensation include: Bleeding Infection Alcohol.
Ascites and Hepatorenal Syndrome: Pathophysiology and Management
Cláudia Fagundes, MD, Pere Ginès, MD, PhD 
Acute Kidney Injury in Patients With Cirrhosis: Perils and Promise
Vasoconstrictor Therapy for the Hepatorenal Syndrome
New Developments in Hepatorenal Syndrome
Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis  Guadalupe.
Portal Hypertension and Its Complications
Kidney Disease in the Setting of Liver Failure: Core Curriculum 2013
Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management  Vicente Arroyo, Jordi Colmenero  Journal of.
Volume 130, Issue 4, Pages (April 2006)
Human serum albumin, systemic inflammation, and cirrhosis
Volume 140, Issue 2, Pages e4 (February 2011)
Acute-on chronic liver failure
Vicente Arroyo, Carlos Terra, Pere Ginès  Journal of Hepatology 
Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment
Volume 134, Issue 5, Pages (May 2008)
Andres Cardenas, Pere Ginès  Journal of Hepatology 
Internal medicine L-4 Liver cirrhosis & portal hypertension
Juan A. Oliver, Elizabeth C. Verna  Kidney International 
Volume 41, Issue 3, Pages (September 2004)
Kidney.
Douglas A. Simonetto, MD, Mengfei Liu, MD, Patrick S. Kamath, MD 
Renal dysfunction in cirrhosis is not just a vasomotor nephropathy
Presentation transcript:

Volume 350: April 15, 2004 Number 16 Management of Cirrhosis and Ascites Pere Ginès, M.D., Andrés Cárdenas, M.D., Vicente Arroyo, M.D., and Juan Rodés, M.D. Volume 350: April 15, 2004 Number 16 Management of Cirrhosis and Ascites Pere Ginès, M.D., Andrés Cárdenas, M.D., Vicente Arroyo, M.D., and Juan Rodés, M.D.April 15, 2004April 15, 2004

Pathophysiology of Ascites Pathophysiology of Ascites The chief factor contributing to ascites is splanchnic vasodilatation. Increased hepatic resistance to portal flow due to cirrhosis causes the gradual development of portal hypertension, collateral-vein formation, and shunting of blood to the systemic circulation. As portal hypertension develops, local production of vasodilators, mainly nitric oxide, increases, leading to splanchnic arterial vasodilatation. The chief factor contributing to ascites is splanchnic vasodilatation. Increased hepatic resistance to portal flow due to cirrhosis causes the gradual development of portal hypertension, collateral-vein formation, and shunting of blood to the systemic circulation. As portal hypertension develops, local production of vasodilators, mainly nitric oxide, increases, leading to splanchnic arterial vasodilatation.

In the early stages of cirrhosis, splanchnic arterial vasodilatation is moderate and has only a small effect on the effective arterial blood volume, which is maintained within normal limits through increases in plasma volume and cardiac output. In the advanced stages of cirrhosis, splanchnic arterial vasodilatation is so pronounced that the effective arterial blood volume decreases markedly, and arterial pressure falls. As a consequence, arterial pressure is maintained by homeostatic activation of vasoconstrictor and antinatriuretic factors, resulting in sodium and fluid retention. In the early stages of cirrhosis, splanchnic arterial vasodilatation is moderate and has only a small effect on the effective arterial blood volume, which is maintained within normal limits through increases in plasma volume and cardiac output. In the advanced stages of cirrhosis, splanchnic arterial vasodilatation is so pronounced that the effective arterial blood volume decreases markedly, and arterial pressure falls. As a consequence, arterial pressure is maintained by homeostatic activation of vasoconstrictor and antinatriuretic factors, resulting in sodium and fluid retention.

. The combination of portal hypertension and splanchnic arterial vasodilatation alters intestinal capillary pressure and permeability, facilitating the accumulation of retained fluid within the abdominal cavity. As the disease progresses, there is marked impairment in renal excretion of free water and renal vasoconstriction — changes that lead to dilutional hyponatremia and the hepatorenal syndrome, respectively.. The combination of portal hypertension and splanchnic arterial vasodilatation alters intestinal capillary pressure and permeability, facilitating the accumulation of retained fluid within the abdominal cavity. As the disease progresses, there is marked impairment in renal excretion of free water and renal vasoconstriction — changes that lead to dilutional hyponatremia and the hepatorenal syndrome, respectively.

Figure 2. Probability of Survival among Patients with Cirrhosis, Refractory Ascites, and the Hepatorenal Syndrome. Type 1 hepatorenal syndrome is a progressive impairment in renal function, defined by a doubling of the initial serum creatinine concentration in less than two weeks to a value greater than 2.5 mg per deciliter (221 µmol per liter). Type 2 hepatorenal syndrome is a stable or slowly progressive impairment in renal function that does not meet the criterion for type 1 hepatorenal syndrome. Figure 2. Probability of Survival among Patients with Cirrhosis, Refractory Ascites, and the Hepatorenal Syndrome. Type 1 hepatorenal syndrome is a progressive impairment in renal function, defined by a doubling of the initial serum creatinine concentration in less than two weeks to a value greater than 2.5 mg per deciliter (221 µmol per liter). Type 2 hepatorenal syndrome is a stable or slowly progressive impairment in renal function that does not meet the criterion for type 1 hepatorenal syndrome.

Spontaneous Bacterial Peritonitis Spontaneous Bacterial Peritonitis Spontaneous bacterial peritonitis is characterized by the spontaneous infection of ascitic fluid in the absence of an intraabdominal source of infection. Its prevalence among patients with ascites ranges between 10 and 30 percent. The presence of at least 250 polymorphonuclear cells per cubic millimeter of ascitic fluid is diagnostic of this condition. Aerobic gram-negative bacteria, primarily Escherichia coli, are the most common isolates, although the frequency of episodes caused by gram-positive bacteria has recently increased. Spontaneous bacterial peritonitis involves the translocation of bacteria from the intestinal lumen to the lymph nodes, with subsequent bacteremia and infection of ascitic fluid. Third-generation cephalosporins are the treatment of choice. Spontaneous bacterial peritonitis is characterized by the spontaneous infection of ascitic fluid in the absence of an intraabdominal source of infection. Its prevalence among patients with ascites ranges between 10 and 30 percent. The presence of at least 250 polymorphonuclear cells per cubic millimeter of ascitic fluid is diagnostic of this condition. Aerobic gram-negative bacteria, primarily Escherichia coli, are the most common isolates, although the frequency of episodes caused by gram-positive bacteria has recently increased. Spontaneous bacterial peritonitis involves the translocation of bacteria from the intestinal lumen to the lymph nodes, with subsequent bacteremia and infection of ascitic fluid. Third-generation cephalosporins are the treatment of choice.